NCT06842537

Study of SYH2062 Injection in Healthy Chinese Volunteers

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2062 Injection in Healthy Chinese Volunteers

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of SYH2062 injection in healthy Chinese volunteers

Detailed description

A Phase 1, randomized, double-Blind, placebo-Controlled study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of SYH2062 injection after a single administration in healthy subjects

Conditions

• Healthy Chinese Volunteers

Interventions

Type	Name	Description
DRUG	SYH2062 injection	SYH2062 for sc injection
DRUG	SYH2062-Matching placebo	Normal saline matching volume of SYH2062 doses will be administered

Timeline

• Start date: 2025-03-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-02-24
• Last updated: 2025-04-30

Locations

1 site across 1 country: China